Adam Fox, MD, and Cynthia A. Schandl, MD, PhD, examined the expanding role of biomarker testing and genomic profiling in NSCLC across disease stages.
Cynthia A. Schandl MD, PhD
Advertisement
Cynthia A. Schandl MD, PhD is the Medical Director of Clinical Laboratories/Director of the Division of Clinical Pathology.
Articles by Cynthia A. Schandl MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5